+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sickle Cell Treatment Market - Global Forecast 2026-2032- Product Image
Sickle Cell Treatment Market - Global Forecast 2026-2032- Product Image
Sale

Sickle Cell Treatment Market - Global Forecast 2026-2032

  • Report

  • 190 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6159411
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Sickle Cell Treatment: Executive Summary

Sickle cell treatment is evolving from episodic management toward comprehensive, lifelong care that combines disease-modifying medicines, transfusion support, complication prevention, and potentially curative cellular therapies. Clinical priorities include reducing vaso-occlusive pain, preventing stroke and organ damage, managing anemia, and improving continuity of care across pediatric and adult settings. Access, diagnosis, treatment adherence, specialist capacity, and affordability remain central determinants of outcomes.

Care Models Are Shifting Toward Prevention and Personalization

The treatment landscape is being reshaped by earlier diagnosis, standardized acute-care protocols, preventive monitoring, and broader use of disease-modifying approaches. Newborn screening and pediatric follow-up support earlier intervention, while transcranial Doppler surveillance helps identify children at elevated stroke risk. Curative options, including hematopoietic stem-cell transplantation and emerging gene-based interventions, are expanding therapeutic possibilities but require specialized infrastructure, rigorous eligibility assessment, and long-term follow-up. Delivery models are also placing greater emphasis on coordinated pain care, mental-health support, reproductive counseling, and transition from pediatric to adult services.

Artificial Intelligence Can Strengthen Diagnosis, Triage, and Longitudinal Management

Artificial intelligence can support sickle cell care by assisting image interpretation, identifying patients at risk of complications, improving clinical-trial recruitment, and analyzing longitudinal laboratory and utilization records. Predictive tools may help prioritize follow-up for stroke risk, acute-care recurrence, or declining organ function, while natural-language systems can reduce documentation burden and surface missed preventive actions. Safe deployment depends on representative training data, external validation across ancestries and care settings, transparent clinical oversight, privacy protections, and monitoring for bias. AI should augment-not replace-specialist judgment and patient-centered decision-making.

Regional Priorities Range From Access Expansion to Advanced Therapy Capacity

North America generally combines established specialist networks, newborn screening, transfusion services, and access to advanced therapies, while persistent disparities affect rural, low-income, and underserved communities. Europe benefits from structured health systems and cross-border clinical expertise, but service consistency varies across countries and migrant populations. The Middle East is strengthening specialized hematology services and genetic counseling, with prevention programs particularly relevant where carrier prevalence is elevated. Africa carries a substantial disease burden and requires stronger screening, reliable supplies, pain-care capacity, and decentralized specialist support. Asia-Pacific presents varied readiness, from advanced tertiary centers to settings where diagnosis and treatment access remain limited. Latin America continues to improve diagnostic and specialty capacity, while affordability, geography, and continuity of care remain important constraints.

Economic and Security Groupings Reveal Different Coordination Needs

ASEAN members face uneven screening coverage, specialist availability, and supply-chain resilience, creating opportunities for shared clinical standards and regional referral pathways. BRICS countries encompass major differences in disease prevalence, health-system capacity, and access to advanced therapies, making collaboration on diagnostics, evidence generation, and affordable production particularly relevant. The European Union can leverage coordinated standards, cross-border expertise, and research collaboration while addressing unequal access between member states. G7 systems generally have strong research and specialist capabilities but must continue reducing racial, geographic, and socioeconomic disparities. GCC countries can build on concentrated healthcare investment and genetic-screening initiatives, while NATO members may benefit from interoperable emergency-care protocols and continuity planning for complex chronic disease services.

Country Systems Differ in Screening, Specialist Access, and Treatment Readiness

Australia has established hematology expertise but must address geographic dispersion and culturally responsive care. Brazil and Mexico continue to require stronger regional access, reliable diagnostics, and integrated public-health follow-up. Canada and the United States have advanced specialist services, although access and outcomes vary across Indigenous, rural, and underserved populations. China and India are expanding diagnostic and treatment capacity while facing substantial geographic and population-scale disparities. France, Germany, Italy, Spain, and the United Kingdom have mature clinical capabilities, with ongoing priorities involving equitable access, transition care, and consistent standards. Japan and South Korea have sophisticated medical infrastructure and research capacity, while continued attention to case identification, specialist coordination, and patient-support pathways remains important. Russia’s needs include dependable diagnostic networks, specialist availability across wide territories, and continuity of essential care.

Industry Leaders Should Prioritize Integrated, Equitable, Evidence-Based Care

Leaders should strengthen end-to-end care pathways linking screening, confirmatory diagnosis, preventive monitoring, acute treatment, chronic disease management, and specialist referral. Investments should focus on interoperable patient records, workforce training, reliable access to essential medicines and blood products, and culturally competent patient education. Organizations developing advanced therapies should pair innovation with transparent eligibility criteria, durable follow-up, affordability planning, and real-world evidence collection. Partnerships with public-health agencies, patient organizations, laboratories, and community providers can improve case finding and adherence. AI initiatives should begin with clearly defined clinical needs, validated datasets, human oversight, and measurable safety and equity outcomes.

Methodology: Evidence Synthesis Across Clinical, Policy, and Access Dimensions

This executive summary uses a structured qualitative synthesis of established clinical practice principles, public-health priorities, treatment pathways, and health-system considerations relevant to sickle cell treatment. The assessment organizes evidence across therapeutic innovation, diagnosis, prevention, acute and chronic care, regional conditions, group-level coordination, and country-level implementation factors. It emphasizes corroborated clinical and policy themes rather than unsupported numerical claims. Interpretation should be updated as clinical guidelines, regulatory decisions, outcomes evidence, screening policies, and access conditions change.

Sustainable Progress Depends on Connecting Innovation With Everyday Care

Sickle cell treatment is advancing, but meaningful improvement depends on translating therapeutic progress into dependable access across the full patient journey. Earlier identification, preventive monitoring, coordinated multidisciplinary care, and responsible adoption of advanced therapies can reduce avoidable complications and improve quality of life. The strongest strategies will combine clinical evidence with health-equity planning, resilient delivery systems, patient partnership, and accountable use of digital tools. Progress should therefore be judged not only by scientific breakthroughs, but also by whether patients can receive timely, continuous, and appropriate care.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Sickle Cell Treatment Market, by Drug Class
7.1. Introduction
7.2. Crizanlizumab
7.3. Hydroxyurea
7.4. L-Glutamine
7.5. Voxelotor
8. Sickle Cell Treatment Market, by Therapy Type
8.1. Introduction
8.2. Advanced Therapy
8.2.1. Gene Editing
8.2.2. Gene Therapy
8.3. Conventional Therapy
8.3.1. Blood Transfusion
8.3.2. Bone Marrow Transplantation
8.3.3. Hydroxyurea
8.3.4. L-Glutamine
9. Sickle Cell Treatment Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.2.1. Biologics
9.2.2. Transfusion
9.3. Oral
10. Sickle Cell Treatment Market, by Patient Age Group
10.1. Introduction
10.2. Adult
10.3. Pediatric
11. Sickle Cell Treatment Market, by End User
11.1. Introduction
11.2. Home Care
11.3. Hospitals
11.4. Specialty Clinics
12. Sickle Cell Treatment Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Sickle Cell Treatment Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Sickle Cell Treatment Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Amgen Inc.
16.2. AstraZeneca plc
16.3. Biogen Inc.
16.4. Biomarin Pharmaceutical Inc.
16.5. Bluebird Bio, Inc.
16.6. Bristol-Myers Squibb Company
16.7. CRISPR Therapeutics AG
16.8. Editas Medicine, Inc.
16.9. Eli Lilly and Company
16.10. Gilead Sciences, Inc.
16.11. Jazz Pharmaceuticals plc
16.12. Johnson & Johnson Services, Inc.
16.13. Merck & Co., Inc.
16.14. Novartis AG
16.15. Pfizer Inc.
16.16. Precision BioSciences, Inc.
16.17. Roche Holding AG
16.18. Sangamo Therapeutics, Inc.
16.19. Sanofi S.A.
16.20. Takeda Pharmaceutical Company Limited
16.21. Vertex Pharmaceuticals Incorporated
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Sickle Cell Treatment Market, Years Considered for the Study
FIGURE 2. Global Sickle Cell Treatment Market, Research Design
FIGURE 3. Global Sickle Cell Treatment Market, Research Framework
FIGURE 4. Global Sickle Cell Treatment Market, Data Triangulation
FIGURE 5. Global Sickle Cell Treatment Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Sickle Cell Treatment Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 7. Global Sickle Cell Treatment Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Sickle Cell Treatment Market Size, by Therapy Type, 2025 vs 2032 (%)
FIGURE 9. Global Sickle Cell Treatment Market Size, by Therapy Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Sickle Cell Treatment Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Sickle Cell Treatment Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Sickle Cell Treatment Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 13. Global Sickle Cell Treatment Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Sickle Cell Treatment Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Sickle Cell Treatment Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Sickle Cell Treatment Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Sickle Cell Treatment Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Sickle Cell Treatment Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Sickle Cell Treatment Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Sickle Cell Treatment Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Sickle Cell Treatment Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Sickle Cell Treatment Market Segmentation & Coverage
TABLE 2. Global Sickle Cell Treatment Market Size, 2017-2032 (USD Million)
TABLE 3. Global Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 4. Global Crizanlizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Crizanlizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Crizanlizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Hydroxyurea Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Hydroxyurea Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Hydroxyurea Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global L-Glutamine Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global L-Glutamine Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global L-Glutamine Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Voxelotor Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Voxelotor Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Voxelotor Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 17. Global Advanced Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Advanced Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Advanced Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Gene Editing Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Gene Editing Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Gene Editing Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Gene Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Conventional Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Conventional Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Conventional Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Blood Transfusion Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Blood Transfusion Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Blood Transfusion Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Bone Marrow Transplantation Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Bone Marrow Transplantation Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Bone Marrow Transplantation Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Hydroxyurea Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Hydroxyurea Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Hydroxyurea Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global L-Glutamine Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global L-Glutamine Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global L-Glutamine Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 42. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Biologics Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Biologics Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Biologics Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Transfusion Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Transfusion Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Transfusion Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 55. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 62. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Sickle Cell Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific Sickle Cell Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Asia-Pacific Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 74. Asia-Pacific Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 75. Asia-Pacific Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 76. Asia-Pacific Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 77. Asia-Pacific Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 78. Asia-Pacific Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 79. Asia-Pacific Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 80. Asia-Pacific Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 81. North America Sickle Cell Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. North America Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 83. North America Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 84. North America Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 85. North America Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 86. North America Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 87. North America Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 88. North America Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 89. North America Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 90. Latin America Sickle Cell Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Latin America Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 92. Latin America Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 93. Latin America Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 94. Latin America Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 95. Latin America Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 96. Latin America Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 97. Latin America Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 98. Latin America Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 99. Europe Sickle Cell Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Europe Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 101. Europe Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 102. Europe Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 103. Europe Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 104. Europe Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 105. Europe Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 106. Europe Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 107. Europe Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 108. Middle East Sickle Cell Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 109. Middle East Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 110. Middle East Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 111. Middle East Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 112. Middle East Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 113. Middle East Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 114. Middle East Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 115. Middle East Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 116. Middle East Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 117. Africa Sickle Cell Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 118. Africa Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 119. Africa Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 120. Africa Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 121. Africa Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 122. Africa Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 123. Africa Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 124. Africa Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 125. Africa Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 126. Global Sickle Cell Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. ASEAN Sickle Cell Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 128. ASEAN Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 129. ASEAN Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 130. ASEAN Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 131. ASEAN Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 132. ASEAN Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 133. ASEAN Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 134. ASEAN Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 135. ASEAN Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 136. GCC Sickle Cell Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 137. GCC Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 138. GCC Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 139. GCC Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 140. GCC Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 141. GCC Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 142. GCC Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 143. GCC Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 144. GCC Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 145. European Union Sickle Cell Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 146. European Union Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 147. European Union Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 148. European Union Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 149. European Union Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 150. European Union Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 151. European Union Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 152. European Union Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 153. European Union Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 154. BRICS Sickle Cell Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 155. BRICS Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 156. BRICS Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 157. BRICS Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 158. BRICS Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 159. BRICS Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 160. BRICS Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 161. BRICS Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 162. BRICS Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 163. G7 Sickle Cell Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 164. G7 Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 165. G7 Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 166. G7 Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 167. G7 Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 168. G7 Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 169. G7 Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 170. G7 Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 171. G7 Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 172. NATO Sickle Cell Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 173. NATO Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 174. NATO Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 175. NATO Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 176. NATO Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 177. NATO Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 178. NATO Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 179. NATO Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 180. NATO Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 181. Global Sickle Cell Treatment Market Size, by Country, 2017-2032 (USD Million)
TABLE 182. United States Sickle Cell Treatment Market Size, 2017-2032 (USD Million)
TABLE 183. United States Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 184. United States Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 185. United States Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 186. United States Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 187. United States Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 188. United States Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 189. United States Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 190. United States Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 191. Canada Sickle Cell Treatment Market Size, 2017-2032 (USD Million)
TABLE 192. Canada Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 193. Canada Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 194. Canada Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 195. Canada Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 196. Canada Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 197. Canada Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 198. Canada Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 199. Canada Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 200. Mexico Sickle Cell Treatment Market Size, 2017-2032 (USD Million)
TABLE 201. Mexico Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 202. Mexico Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 203. Mexico Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 204. Mexico Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 205. Mexico Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 206. Mexico Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 207. Mexico Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 208. Mexico Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 209. Brazil Sickle Cell Treatment Market Size, 2017-2032 (USD Million)
TABLE 210. Brazil Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 211. Brazil Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 212. Brazil Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 213. Brazil Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 214. Brazil Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 215. Brazil Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 216. Brazil Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 217. Brazil Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 218. United Kingdom Sickle Cell Treatment Market Size, 2017-2032 (USD Million)
TABLE 219. United Kingdom Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 220. United Kingdom Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 221. United Kingdom Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 222. United Kingdom Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 223. United Kingdom Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 224. United Kingdom Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 225. United Kingdom Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 226. United Kingdom Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 227. Germany Sickle Cell Treatment Market Size, 2017-2032 (USD Million)
TABLE 228. Germany Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 229. Germany Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 230. Germany Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 231. Germany Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 232. Germany Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 233. Germany Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 234. Germany Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 235. Germany Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 236. France Sickle Cell Treatment Market Size, 2017-2032 (USD Million)
TABLE 237. France Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 238. France Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 239. France Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 240. France Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 241. France Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 242. France Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 243. France Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 244. France Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 245. Russia Sickle Cell Treatment Market Size, 2017-2032 (USD Million)
TABLE 246. Russia Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 247. Russia Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 248. Russia Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 249. Russia Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 250. Russia Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 251. Russia Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 252. Russia Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 253. Russia Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 254. Italy Sickle Cell Treatment Market Size, 2017-2032 (USD Million)
TABLE 255. Italy Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 256. Italy Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 257. Italy Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 258. Italy Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 259. Italy Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 260. Italy Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 261. Italy Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 262. Italy Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 263. Spain Sickle Cell Treatment Market Size, 2017-2032 (USD Million)
TABLE 264. Spain Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 265. Spain Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 266. Spain Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 267. Spain Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 268. Spain Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 269. Spain Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 270. Spain Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 271. Spain Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 272. China Sickle Cell Treatment Market Size, 2017-2032 (USD Million)
TABLE 273. China Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 274. China Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 275. China Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 276. China Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 277. China Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 278. China Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 279. China Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 280. China Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 281. India Sickle Cell Treatment Market Size, 2017-2032 (USD Million)
TABLE 282. India Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 283. India Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 284. India Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 285. India Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 286. India Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 287. India Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 288. India Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 289. India Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 290. Japan Sickle Cell Treatment Market Size, 2017-2032 (USD Million)
TABLE 291. Japan Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 292. Japan Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 293. Japan Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 294. Japan Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 295. Japan Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 296. Japan Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 297. Japan Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 298. Japan Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 299. Australia Sickle Cell Treatment Market Size, 2017-2032 (USD Million)
TABLE 300. Australia Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 301. Australia Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 302. Australia Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 303. Australia Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 304. Australia Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 305. Australia Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 306. Australia Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 307. Australia Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 308. South Korea Sickle Cell Treatment Market Size, 2017-2032 (USD Million)
TABLE 309. South Korea Sickle Cell Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 310. South Korea Sickle Cell Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 311. South Korea Sickle Cell Treatment Market Size, by Advanced Therapy, 2017-2032 (USD Million)
TABLE 312. South Korea Sickle Cell Treatment Market Size, by Conventional Therapy, 2017-2032 (USD Million)
TABLE 313. South Korea Sickle Cell Treatment Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 314. South Korea Sickle Cell Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 315. South Korea Sickle Cell Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 316. South Korea Sickle Cell Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 317. Global Sickle Cell Treatment Market Share, by Key Player, 2025
TABLE 318. Global Sickle Cell Treatment Market, Key Experts

Companies Mentioned

  • Amgen Inc.
  • AstraZeneca plc
  • Biogen Inc.
  • Biomarin Pharmaceutical Inc.
  • Bluebird Bio, Inc.
  • Bristol-Myers Squibb Company
  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Jazz Pharmaceuticals plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Precision BioSciences, Inc.
  • Roche Holding AG
  • Sangamo Therapeutics, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated

Related Topics

Related Reports

Sickle Cell Disease Treatment Market - Global Forecast 2026-2032 - Product Image

Sickle Cell Disease Treatment Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Sickle Cell Disease Treatment Market Report 2026 - Product Image

Sickle Cell Disease Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Sickle Cell Disease Treatment Market Report Size, Share, Trends and Forecast by Treatment Type, End User, and Region, 2026-2034 - Product Image

Sickle Cell Disease Treatment Market Report Size, Share, Trends and Forecast by Treatment Type, End User, and Region, 2026-2034

  • Report
  • 149 Pages
  • Global
From
Sickle Cell Disease Treatment - Global Strategic Business Report - Product Image

Sickle Cell Disease Treatment - Global Strategic Business Report

  • Report
  • 148 Pages
  • Global
From
Sickle Cell Disease Treatment Market Outlook 2026-2034: Market Share, and Growth Analysis by Treatment Type, Patient Age Group, End User - Product Image

Sickle Cell Disease Treatment Market Outlook 2026-2034: Market Share, and Growth Analysis by Treatment Type, Patient Age Group, End User

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.